Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factor studies in oncology: osteosarcoma as a clinical example.

S M Bentzen1

  • 1Biostatistics in Oncology Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK. bentzen@graylab.ac.uk

International Journal of Radiation Oncology, Biology, Physics
|February 15, 2001
PubMed
Summary

Most oncology prognostic studies, especially for rare cancers like osteosarcoma, lack the statistical power to identify significant factors due to small sample sizes. Improving study design is crucial for clinical impact.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence in Health Care: A Rallying Cry for Critical Clinical Research and Ethical Thinking.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

The Effect of Body Mass Index and Residence in Food Priority Areas on Patterns-of-Care and Cancer Outcomes in Patients With Stage III Non-Small Cell Lung Cancer.

International journal of radiation oncology, biology, physics·2023
Same author

Pediatric Normal Tissue Effects in the Clinic (PENTEC): An International Collaboration to Analyse Normal Tissue Radiation Dose-Volume Response Relationships for Paediatric Cancer Patients.

Clinical oncology (Royal College of Radiologists (Great Britain))·2019
Same author

Abstracts from the 8th Annual Meeting of the Scientific Association of Swiss Radiation Oncology (SASRO).

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

A toast to the silver anniversary of Clinical Oncology: a quarter of a century of advances in evidence-based radiation dose fractionation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2014
Same author

Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.

Clinical oncology (Royal College of Radiologists (Great Britain))·2012

Area of Science:

  • Oncology
  • Biostatistics
  • Epidemiology

Background:

  • Prognostic factor studies are common in oncology but often have limited clinical impact.
  • Low statistical power due to small sample sizes is a major limitation.
  • Osteosarcoma, a rare cancer, exemplifies these challenges.

Purpose of the Study:

  • To evaluate the impact of statistical power on prognostic factor identification in oncology.
  • To assess the adequacy of sample sizes in published osteosarcoma prognostic studies.
  • To illustrate the importance of sample size using bootstrap resampling.

Main Methods:

  • Literature search of MEDLINE (1975-1998) for osteosarcoma prognostic factor studies.
  • Analysis of 158 osteosarcoma cases treated with surgery alone.

Related Experiment Videos

  • Bootstrap resampling applied to survival data to assess power and sample size effects.

    • Main Results:

    • Most reviewed studies (3/4) included fewer than 100 patients, limiting their ability to detect prognostic factors.
    • Over 20 potential prognostic factors were investigated across studies, but synthesis was hampered by heterogeneity and poor reporting.
    • Bootstrap resampling demonstrated that typical study sizes would likely miss significant prognostic factors.

    Conclusions:

    • Current prognostic studies in oncology, particularly for rare diseases, are often underpowered.
    • There is a critical need for improved study design, conduct, and reporting in cancer prognostic research.
    • Enhanced statistical power is essential for generating clinically relevant prognostic information.